---
pmid: '17981115'
title: Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting
  healthy vessels.
authors:
- Fischer C
- Jonckx B
- Mazzone M
- Zacchigna S
- Loges S
- Pattarini L
- Chorianopoulos E
- Liesenborghs L
- Koch M
- De Mol M
- Autiero M
- Wyns S
- Plaisance S
- Moons L
- van Rooijen N
- Giacca M
- Stassen JM
- Dewerchin M
- Collen D
- Carmeliet P
journal: Cell
year: '2007'
full_text_available: false
doi: 10.1016/j.cell.2007.08.038
---

# Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
**Authors:** Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P
**Journal:** Cell (2007)
**DOI:** [10.1016/j.cell.2007.08.038](https://doi.org/10.1016/j.cell.2007.08.038)

## Abstract

1. Cell. 2007 Nov 2;131(3):463-75. doi: 10.1016/j.cell.2007.08.038.

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without 
affecting healthy vessels.

Fischer C(1), Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, 
Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance 
S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, 
Carmeliet P.

Author information:
(1)Department for Transgene Technology and Gene Therapy, VIB, 3000, Leuven, 
Belgium.

Comment in
    Cell. 2007 Nov 2;131(3):443-5. doi: 10.1016/j.cell.2007.10.023.

Novel antiangiogenic strategies with complementary mechanisms are needed to 
maximize efficacy and minimize resistance to current angiogenesis inhibitors. We 
explored the therapeutic potential and mechanisms of alphaPlGF, an antibody 
against placental growth factor (PlGF), a VEGF homolog, which regulates the 
angiogenic switch in disease, but not in health. alphaPlGF inhibited growth and 
metastasis of various tumors, including those resistant to VEGF(R) inhibitors 
(VEGF(R)Is), and enhanced the efficacy of chemotherapy and VEGF(R)Is. alphaPlGF 
inhibited angiogenesis, lymphangiogenesis, and tumor cell motility. Distinct 
from VEGF(R)Is, alphaPlGF prevented infiltration of angiogenic macrophages and 
severe tumor hypoxia, and thus, did not switch on the angiogenic rescue program 
responsible for resistance to VEGF(R)Is. Moreover, it did not cause or enhance 
VEGF(R)I-related side effects. The efficacy and safety of alphaPlGF, its 
pleiotropic and complementary mechanism to VEGF(R)Is, and the negligible 
induction of an angiogenic rescue program suggest that alphaPlGF may constitute 
a novel approach for cancer treatment.

DOI: 10.1016/j.cell.2007.08.038
PMID: 17981115 [Indexed for MEDLINE]
